Contact FAQ

2026 Roundtable: Ethics, Trust + Patient Centricity in Pharma

Bioethics International & EY’s 17th Annual Pharmaceutical Executive Roundtable on Ethics, Trust, and Patient Centricity

Co-hosted with Yale Medicines Access Network (YMAN), Yale Program for Biomedical Ethics, and Scientific American

This annual roundtable is the leading forum for senior leaders in healthcare, including industry, patient groups, and academia, to discuss the state of bioethics and patient centricity in medicine development and access and the role of the pharmaceutical sector.

Register your interest HERE to Join us in 2027.

When and where?
June 8, 2026
EY Offices, 48th Floor, 401 9th Ave, NY 10001.

Seats are limited. If your application is unsuccessful this year, we will refund your donation in full and invite you next year.


AGENDA  

8:00-8:30am   Breakfast + Registration

8:30-8:35        Welcome.  Arda Ural, Head of Life Sciences, Americas, EY

 

8:35-8:45        Jennifer Miller, Co-Director, Program for Biomedical Ethics, Associate Professor, Yale School of Medicine; Founder, Bioethics International, CEO, Good Pharma Scorecard. Why we are here and what we hope to accomplish

 

8:45-9:00        Patrice Matchaba, Former Group Head Novartis Global Health; CEO of Gates Medical Research Institute

 

9:00-9:20        Robert Califf, Former FDA Commissioner (in person)

 

9:20-10:20      Transparency, Data Sharing, and the Path Forward for Clinical Research. How Transparent Is Transparent Enough?

What constitutes meaningful transparency in clinical research today and how close is the pharmaceutical sector to delivering on that vision? This session will examine transparency goals and progress against evolving expectations for trials, anchored by the findings of the latest Good Pharma Scorecard (GPS) evaluating sponsor registration, results reporting, FDAAA compliance, publication, and data sharing practices. Panelists from high-performing organizations (“bright spots”) will share strategies associated with their success. Looking ahead, we will also revisit the GPS framework itself asking what may need to be recalibrate to better meet stakeholder needs.

 

9:20-9:30 Opening remarks. Jennifer Miller, GPS measures, performance trends, findings

9:30-10:15  Panel

  • Joseph Ross, Professor of Medicine, Yale School of Medicine
  • Celine Enderlin, Global Head, Clinical Disclosure Office, Novartis
  • Kali Tarascavage, Clinical Transparency Lead, Otsuka
  • Daniel Boisvert, Senior Director, Head of Data Stewardship, Biogen
  • Michelle Clausen, Head of Clinical Trial Disclosure and Expanded Access, Pfizer
  • Elizabeth Fox, SVP, Clinical Trials Research, Associate Director for Clinical Research, Comprehensive Cancer Center, St. Jude Children’s Research Hospital
  • Allison Chou, Director, Clinical Trial Disclosure & Transparency, Takeda

 

10:15-10:25 Poll + full group discussion. If the GPS adds one new transparency metric in 2027, what should it be and why?

 

10:25-10:40    Coffee Break

 

10:40-11:30     The Ethics of Tradeoffs: Inside C-Suite Decision-Making in BioPharma

This fireside chat will discuss how C-level executives are thinking about / conceptualizing bioethics issues and prioritizing and tackling them given incentives, resource constraints and competing goals.

  • Amrit Ray, Former Global President R&D, Pfizer; Hastings Center; WCG
  • Abdul Mullick, CEO, Kyowa Kirin
  • Lobna Salem, Chief Medical Officer, Viatris
  • Paul Houri, Chief Quality Officer, Bristol Myers Squibb
  • Kinnari Patel, CEO, RTW Institute
  • Jethro Ekuta, Chief Regulatory Officer, Ascendis Pharma, Former FDA Officer

 

11:30-12:30    What Does a Representative Clinical Trial Look Like and Why Do Some Sponsors Consistently Achieve It While Others Do Not?

This session will explore what it means and takes to design clinical trials that are both high-quality and representative of the patients they aim to serve.  Discussion will be informed by new Good Pharma Scorecard (GPS) findings on sector performance for representation in oncology pivotal trials and the results of a bright spot analysis on factors associated with successful and consistent representation of demographic groups in oncology research- moving discussions beyond benchmarking to focus on implementation: how these practices can be embedded into R&D processes, aligned with incentives, and scaled across organizations. The session will also interrogate whether current metrics adequately capture what matters and where the field should go next.

 

11:30-11:40 Opening remarks. Jennifer Miller, GPS measures, performance trends, findings

11:40-12:20  Panel

  • Moderator. Tanvee Varma, Clinical Fellow, Medicine, Brigham and Women’s Hospital
  • Pierre Theodore, Executive Director, Population Science and Development, Roche
  • Julie Gralow, CMO, ASCO
  • Jane Perlmutter, PCORI Advisory board member, Lung Cancer Foundation of America, Patient Advocate, Komen Advocate In Science
  • Megan Wanzo, Associate Director, Health Equity, BMS
  • Kasey Boynton, Senior Director, Global Operations and Community Partnerships, Sanofi

 

12:20-12:30 Poll and Full group discussions.  EY summarizes top 3 strategies the room thinks are most impactful in facilitating representative clinical research. The room discusses the top 2 strategies which could be added to the GPS and how to benchmark implementation.

 

12:30-12:35    Group Photo

12:35-1:05      Lunch Break

 

1:05-1:15pm   Susan Garfield, Chief Population Health, EY

 

1:15-2:25         Physical Access to Novel Medicines, in the LMICs where Trials are conducted for US FDA Approvals

This workshop will focus on efforts to expand global market access to novel medicines. Dr. Miller will kick off the session presenting data about market access to novel medicines in the LMIC countries where clinical trials are conducted for FDA approvals. Catalyst speakers and roundtable participants will discuss access challenges and why the data are what they are, efforts to advance access, areas where there has been success, and promising opportunities for improvement. We will conclude the session discussing and refining a set of metrics for tracking global market access to novel medicines, focusing on countries where trials are undertaken for US FDA approvals.

 

1:15-1:25 Opening remarks. Jennifer Miller, Sector performance trends and draft metrics for market access to medicines in LMICs hosting trials for FDA approvals

1:25-2:10 Panel.

  • Marc Wilenzick, Senior Counsel, Regulatory, FDA, & Market Access, Regeneron
  • Craig Spencer, Associate Professor, Health Services, Policy and Practice, Brown School of Public Health; Council on Foreign Relations; Board of advisors, Doctors Without Borders
  • Justin King, Lead Global Study Manager, Early Development Oncology Operations, Sanofi
  • Vibhooti Ashar, Global Market Access & Pricing, BMS
  • Kim Green, Global Program Director, Primary Healthcare, PATH, Coalition for NCDs
  • Jeremy Schwartz, Associate Professor of Medicine, Yale School of Medicine, Co-Director, Yale Medicines Access Network (YMAN)
  • Vasee Moorthy, Senior Science and Strategy Advisor, World Health Organization (WHO)
  • Tariro Makadzange, CEO, Africa Clinical Research Network (ACRN)

 

Poll. What are the top 2-3 things we could measure to move access in the right direction for LMICs hosting trials?

2:10-2:25  Full group discussions. How could we scorecard sponsors on this issue?

 

2:25-2:45        Coffee Break

 

2:45-3:00        Arthur Caplan, NYU School of Medicine

 

3:30-4:30        Workshop. Patient Centricity in the Pharma Sector, Goals and Metrics for the US

This session will explore what a unified and actionable framework for measuring patient centricity in the biopharma sector could look like, and how initiatives such as the Good Pharma Scorecard can support accountability, benchmarking, and implementation across the industry. The discussion will begin by reviewing the findings of a literature review characterizing core dimensions of patient centricity across biopharma operations, extending beyond patient engagement in clinical trials to encompass broader organizational practices. We will then break into small groups to explore the below questions and conclude with a panel discussion on concrete recommendations for measuring, communicating, and strengthening patient centricity efforts, highlighting both promising practices and areas where additional progress is needed.

 

3-3:10 Opening Remarks. Jennifer Miller, Patient-centeredness in the pharmaceutical sector: A taxonomy of core dimensions based on a scoping review of the literature

3:10-3:40 Small break out groups.

3:40-3:50 Report back from groups on top 3-5 important and doable metrics

3:50-4:30pm Panel

  • Moderator. Jane Perlmutter, PCORI, Lung Cancer Foundation of America, Komen
  • Pam Gavin, CEO, NORD
  • TréLaRosa, Foundation for the National Institutes of Health
  • Shelley Fuld Nasso, CEO, Cancer Nation
  • Rebekah Angove, Chief Science Officer, Patient Advocate Foundation
  • Annette Bakker CEO, Children’s Tumor Foundation
  • R. Meloro, Global Team Lead, Medical Communications & Content, Pfizer
  • Wendy Erler, SVP, Patient Affairs, Sarepta Therapeutics
  • Emma Andrews, VP US Business Policy and Patient Affairs and Public Policy, Pfizer
  • Amy Akers Teets, Global Head Patient Strategy, Specialty Care, Sanofi
  • Liz Rogers, VP, Head of Clinical Operations, CSL

 

4:30-4:45pm   2026 Roundtable Consensus Priorities: Toward a New Accountability Framework for Bioethical and Patient Centered Biopharma

Poll 1. What is your 1 big take away from the day?

Polling results. Sophia Pudik, Business Consulting, EY

1-minute: What is your 1 big take away from the day?

  • Tanisha Carino, Head of strategy U.S. corporate, UCB; Board Member, WHO Foundation
  • Steve Sammut, Wharton School of Management, Alta Semper Capital; Visiting faculty, Indian School of Business and Strathmore University Business School in Nairobi, Kenya
  • Amrit Ray, ex-Global President R&D, Pfizer; Board of Directors, Hastings Center; WCG
  • Craig Spencer, Associate Professor, Health Services, Policy and Practice, Brown School of Public Health; Council on Foreign Relations; Advisory Board, Doctors Without Borders
  • Julie Gralow, CMO, ASCO

 

4:45-5pm  Closing Remarks

  • Lauren Rogge, Principal, Climate Change and Sustainability, EY
  • Jennifer E. Miller, Co-Director, Program for Biomedical Ethics, Associate Professor, Yale School of Medicine, Bioethics International, Good Pharma Scorecard

 

5:00-6:00        Networking and Drinks

6:15-7:30        Dinner at Kyma (Speakers and Bioethics Leadership Forum)

 

Roundtable Co-Hosts

  • Bioethics International (BEI) is a 501c3 public charity, founded in 2005, to help advance ethics, trustworthiness, patient-centricity, and social responsibility in healthcare.
  • EY. EY’s purpose is building a better working world. The insights and quality services EY provide help build trust and confidence in the capital markets and in economies the world over. They develop outstanding leaders who team to deliver on their promises to all our stakeholders. In so doing, EY plays a critical role in building a better working world for its people, for clients and communities.

Additional Partners

  • Scientific American. Scientific American is the authority on science and technology for a general audience, with coverage that explains how research changes our understanding of the world and shapes our lives. First published in 1845, Scientific Americanis the longest continuously published magazine in the US. The magazine has published articles by more than 150 Nobel Prize-winning scientists and built a loyal following of influential and forward-thinking readers. The archives include articles penned by Albert Einstein, Thomas Edison, Jonas Salk, Marie Curie, Stephen Hawking, Franklin D. Roosevelt, Stephen Jay Gould, Bill Gates, and more.
  • Yale Program for Biomedical Ethics. The Yale Program for Biomedical Ethics incorporates a diverse group that brings a wide range of experience and expertise to the table, including faculty and staff from the Schools of Medicine, Nursing, Law, Divinity, Public Health, as well as Yale New Haven Hospital staff, and others who share a common interest in education, research, and clinical practice in the field of medical ethics. Our program coordinates the ethics education of Yale medical students over the course of their four years, including assistance for those who choose to write their thesis in this area. In addition, educational programs are provided for other members of the Yale medical community, such as journal clubs, working groups and special conferences.
  • Good Pharma Scorecard (GPS). The Good Pharma Scorecard is a ranking and rating of pharma companies on their bioethics, social responsibility, and patient-centricity performance. Through the Scorecard, we develop benchmarks for what constitutes ‘good’ socially responsible practices. We then use these benchmarks to measure and rate company performance annually, helping recognize good practices, catalyze reform where needed, and track progress on goals over time.
  • Yale Medicines Access Network (YMAN)